Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices
Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent. Nurses and advanced practice providers collaborate with physicians to manage cutaneous toxicities by administering comedications, modifying amivantamab dose, and educating patients.
Authors
- Shahnaz Singh-Kandah
- Karen Xia
- Stephanie M. Gallitano
- Catherine A. Shu (ORCID: https://orcid.org/0000-0003-0765-7665)
- Denise D’Andrea
- Kaiwen Wang (ORCID: https://orcid.org/0000-0003-3857-4790)
- Andy Lain Johnson
- Lindsay Dougherty
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Janssen (Belgium) (BE)
- Columbia University Irving Medical Center (US)
- Texas Health Dallas (US)
- Janssen Scientific Affairs (United States)
Publication Details
- Journal
- Clinical journal of oncology nursing
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1188/24.cjon.1-8.ap
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28